10-Q: Rapport Therapeutics Reports Positive RAP-219 Seizure Trial Results

Rapport Therapeutics, a clinical-stage biotechnology company, announced positive topline results from its Phase 2a trial of RAP-219 for drug-resistant focal onset seizures, alongside a significant capital raise and continued operating losses.

Summary

• Rapport Therapeutics, a clinical-stage biotechnology company, reported positive topline results from its Phase 2a proof-of-concept trial of RAP-219 in adult patients with drug-resistant focal onset seizures, meeting primary and secondary endpoints.
• The trial demonstrated a statistically significant reduction in long episodes (an objective electrographic biomarker) and a clinically meaningful reduction in clinical seizures compared with baseline over the 8-week treatment period.
• RAP-219 was generally well tolerated in the Phase 2a trial.
• The U.S. FDA placed a clinical hold on the Phase 2 proof-of-concept trial of RAP-219 for diabetic peripheral neuropathic pain (DPNP) in Q4 2024, requesting additional information and amendments specific to the protocol design.
• The Phase 2 proof-of-concept trial for RAP-219 in bipolar mania is currently enrolling patients, with topline results expected in the first half of 2027.
• The company completed an underwritten public offering in September 2025, raising approximately $269.4 million in net proceeds.
• Rapport Therapeutics incurred net losses of $26.9 million for the three months ended September 30, 2025, and $77.7 million for the nine months ended September 30, 2025.
• The accumulated deficit reached $201.5 million as of September 30, 2025.
• Cash, cash equivalents, and short-term investments totaled $513.0 million as of September 30, 2025, which is expected to fund operating expenses and capital expenditure requirements into the second half of 2029.
• Research and development expenses increased to $22.3 million for Q3 2025 (from $15.5 million in Q3 2024) and $64.5 million for the nine months ended September 30, 2025 (from $43.7 million in 2024).
• General and administrative expenses increased to $7.7 million for Q3 2025 (from $6.1 million in Q3 2024) and $22.1 million for the nine months ended September 30, 2025 (from $15.8 million in 2024).

Sentiment

Score: 7

Explanation: The positive Phase 2a results for RAP-219 in focal onset seizures are a significant clinical de-risking event and a major positive. The substantial capital raise further strengthens the company's financial position, extending its runway. However, the clinical hold on the DPNP trial and continued operating losses temper the overall sentiment, indicating ongoing development risks and cash burn.

Positives

• Positive topline results from the Phase 2a trial of RAP-219 in drug-resistant focal onset seizures, meeting primary and secondary endpoints.
• Statistically significant reduction in long episodes (objective electrographic biomarker) and clinically meaningful reduction in clinical seizures observed in the Phase 2a trial.
• RAP-219 was generally well tolerated in the Phase 2a trial.
• Successful completion of an underwritten public offering in September 2025, raising approximately $269.4 million in net proceeds.
• Strong cash position of $513.0 million (cash, cash equivalents, and short-term investments) as of September 30, 2025.
• Existing capital is projected to fund operating expenses and capital expenditure requirements into the second half of 2029.
• Advancement of RAP-219 into Phase 3 trials for focal onset seizures planned for Q3 2026.
• Phase 2 proof-of-concept trial in bipolar mania is currently enrolling patients.

Negatives

• Incurred significant net losses: $26.9 million for the three months ended September 30, 2025, and $77.7 million for the nine months ended September 30, 2025.
• Accumulated deficit of $201.5 million as of September 30, 2025.
• The U.S. FDA placed a clinical hold on the Phase 2 proof-of-concept trial of RAP-219 for diabetic peripheral neuropathic pain (DPNP) in Q4 2024.
• Increased research and development expenses by $6.7 million in Q3 2025 and $20.8 million for the nine months ended September 30, 2025, driven by clinical trial costs and headcount.
• Increased general and administrative expenses by $1.6 million in Q3 2025 and $6.3 million for the nine months ended September 30, 2025, due to headcount and public company costs.
• Interest income decreased by $1.0 million in Q3 2025 compared to Q3 2024 due to decreased cash balances for most of the quarter (before the September offering).

Risks

• Limited operating history and history of significant financial losses, with anticipated continued losses.
• Need for additional funding; inability to raise capital on acceptable terms could delay or eliminate product development/commercialization.
• High dependence on the success of product candidates, particularly RAP-219 for focal onset seizures; failure or delays would materially harm the business.
• Lengthy, expensive, and highly uncertain pharmaceutical product development process.
• Need to prioritize development of certain product candidates over others due to limited resources, potentially missing more profitable opportunities.
• Lengthy, time-consuming, and unpredictable regulatory approval processes (FDA, EMA, MHRA); inability to obtain approval would substantially harm the business.
• Dependence on third-party generated data from preclinical studies and clinical trials for in-licensed product candidates (Janssen).
• Risk that clinical trials fail to replicate positive results from earlier studies.
• Failure to achieve projected development and commercialization goals in announced timeframes could cause delays.
• Product candidates may cause undesirable side effects, delaying/preventing approval or limiting commercial profile.
• Concentrated R&D efforts on nervous system disorders, a field with drug development challenges (e.g., subjective endpoints, placebo effect).
• Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, and payors.
• Uncertainty in the precise number of patients with target diseases, potentially leading to difficulties in clinical trial enrollment or smaller market sizes.
• Reliance on third parties (CROs, NeuroPace) to assist in conducting clinical trials; unsatisfactory performance could delay approval or commercialization.
• Dependence on in-licensed intellectual property (Janssen License); failure to comply with obligations could lead to loss of license rights.
• Inability to obtain and maintain broad patent protection for product candidates could allow competitors to commercialize similar products.
• Inadequate funding for the FDA or other government agencies could hinder timely product development/commercialization.
• Relationships with healthcare providers and payors subject to anti-kickback, fraud, abuse, and other healthcare laws, risking sanctions and reputational harm.
• Coverage and reimbursement may be limited or unavailable, making profitable sales difficult.
• Subject to export/import controls, economic sanctions, and anti-corruption laws, risking criminal liability and other consequences.
• Failure to comply with environmental, health, and safety laws could result in fines or liabilities.
• Risk of cyber-attacks, cybersecurity incidents, or breaches, leading to costs, revenue loss, and disruption.
• Use of new technologies like AI/ML may present new risks and challenges.
• Interim, topline, and preliminary data may change as more patient data becomes available.
• Risk of unexpected costs or delays in completing development and commercialization.
• Risk that regulatory authorities may disagree with the regulatory plan or require additional trials.
• Risk that designations like Fast Track or Breakthrough Therapy may not be obtained or realize intended benefits.
• Risk of accelerated approval withdrawal if confirmatory trials do not verify clinical benefit.
• Unfavorable global economic conditions, political instability, and geopolitical events could adversely affect business.
• Natural disasters, public health crises, or other business interruptions could adversely affect business.
• Reliance on reduced reporting requirements as an emerging growth company and smaller reporting company may make common stock less attractive.
• Significant costs and management time devoted to public company compliance.
• Failure to establish and maintain effective internal control over financial reporting.
• Limitations on the ability to use net operating loss carryforwards and other tax attributes.
• Changes in tax law could adversely affect business.
• Clinical trial and product liability lawsuits could divert resources and could cause substantial liabilities.
• Litigation could divert management attention and harm business.
• Active trading market for common stock may not be sustained.
• Price of common stock may be volatile.
• Operating results may fluctuate significantly.
• Executive officers, directors, and principal stockholders own a significant percentage of common stock and can exert control.
• Sales of substantial number of shares could cause stock price to fall.
• Issuance of additional capital stock will dilute other stockholders.
• No current intention to pay dividends.
• Provisions in corporate charter documents and Delaware law could make acquisition more difficult.
• Bylaws designate certain courts as sole forum for certain actions, limiting stockholders' ability to choose forum.
• May not be able to continue to satisfy Nasdaq listing requirements.

Future Outlook

Rapport Therapeutics expects to continue incurring significant operating losses for the foreseeable future as it advances RAP-219 through late-stage clinical trials, pursues regulatory approvals, and expands its pipeline. The company projects its current cash and investments will fund operations into the second half of 2029. It plans to initiate two Phase 3 trials for RAP-219 in focal onset seizures in Q3 2026 and expects topline results for the bipolar mania trial in H1 2027. Next steps for the DPNP program are anticipated in Q1 2026.

Management Comments

• "We expect to continue to generate operating losses for the foreseeable future."
• "We expect that our cash and cash equivalents and short-term investments will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the issuance of these condensed consolidated financial statements."
• "We believe that our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2029."
• "We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect."
• "We will need to raise substantial additional capital in the future."

Industry Context

Rapport Therapeutics operates in the highly competitive and rapidly evolving neuroscience biotechnology sector, focusing on small molecule precision medicines. Its RAP technology platform aims to overcome limitations of conventional neurology drug discovery by targeting specific neuronal receptor complexes. The positive Phase 2a results for RAP-219 in focal onset seizures position it favorably against competitors, many of whom also pursue treatments for neurological disorders. The clinical hold on the DPNP trial highlights the inherent regulatory challenges in drug development, particularly in complex areas like neuropathic pain. The company's strategy to develop a long-acting injectable formulation of RAP-219 aligns with broader industry trends to improve patient adherence and expand market potential for chronic conditions.

Comparison to Industry Standards

• The Phase 2a proof-of-concept trial for RAP-219 in drug-resistant focal onset seizures utilized a novel study design with intracranial electroencephalography (iEEG) data as a primary endpoint, which is not a standard approach for registrational trials and has not been discussed with the FDA for this purpose.
• The company acknowledges that most neuroactive drugs lack the specificity RAP-219 aims to achieve, often resulting in undesired and intolerable side effects, suggesting a potential differentiated profile compared to traditional neuroscience medications.
• The company notes that many neurological disorders, such as focal onset seizures, bipolar disorder, and peripheral neuropathic pain, rely on subjective patient-reported outcomes as key endpoints, making them more difficult to evaluate than indications with more objective endpoints and often subject to a placebo effect, which is a common challenge in the industry.
• The company does not currently plan to run head-to-head clinical trials evaluating its product candidates against current standards of care, which may make it more challenging to compete due to the lack of direct comparative data.

Related Party Transactions

• Janssen Pharmaceutical NV (a direct subsidiary of Johnson & Johnson, Inc., a founding investor) incurred costs of zero for the nine months ended September 30, 2025 (compared to $69 thousand in 2024) for lab space use.
• Third Rock Ventures LLC (a founding investor) incurred costs of zero for the nine months ended September 30, 2025 (compared to $0.1 million in 2024) for management consulting and start-up support.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical trial results and extended cash runway, but also dilution from recent offering and ongoing risk of losses and future capital raises. Volatility in stock price is a risk.
• Employees: Increased headcount and stock-based compensation indicate growth, but competition for skilled personnel is a risk.
• Customers/Patients: Potential for new treatment options for focal onset seizures, bipolar disorder, and peripheral neuropathic pain, but DPNP trial delay impacts patient access.
• Suppliers/Creditors: Continued reliance on third-party manufacturers and CROs, with potential for increased business, but also risks of supply chain disruptions.
• Regulatory Authorities: Ongoing engagement with FDA for clinical trials and regulatory approvals, including addressing the DPNP clinical hold.

Next Steps

• Present additional efficacy analyses for the Phase 2a focal onset seizure trial later in 2025.
• Present 8-week follow-up results for the Phase 2a focal onset seizure trial in 2026.
• Hold an end-of-Phase 2 meeting with the U.S. FDA in Q4 2025 for RAP-219 in focal onset seizures.
• Initiate an open-label long term safety trial for RAP-219 in focal onset seizures by the end of 2025.
• Expect preliminary results of the open-label long term safety trial in H2 2026.
• Initiate two Phase 3 trials for RAP-219 in focal onset seizures in Q3 2026.
• Continue enrolling patients in the Phase 2 proof-of-concept trial for RAP-219 in bipolar mania, with topline results expected in H1 2027.
• Determine next steps for the RAP-219 DPNP program in Q1 2026.
• Continue to develop a long-acting injectable (LAI) formulation of RAP-219.
• Continue to develop two advanced discovery-stage nicotinic acetylcholine receptor (nAChR) programs for chronic pain and hearing disorders.
• Seek additional financing through equity offerings, debt financings, or other capital sources.

Key Dates

Recommendation

The positive topline Phase 2a results for RAP-219 in drug-resistant focal onset seizures represent a significant de-risking event for Rapport Therapeutics' lead asset, demonstrating both statistical significance and clinical meaningfulness. This strong clinical data, coupled with the successful $269.4 million public offering that extends the cash runway into the second half of 2029, provides substantial financial stability for advancing RAP-219 into pivotal Phase 3 trials. While the DPNP clinical hold and ongoing operating losses are noted, the core value proposition of RAP-219 in a high-unmet-need indication like focal onset seizures, supported by a robust balance sheet, outweighs these concerns for a long-term growth-oriented investor. The company's precision medicine platform and pipeline-in-a-product potential for RAP-219 in other neurological disorders further enhance its attractiveness.

Keywords

Rapport Therapeutics, RAP-219, Focal Onset Seizures, Biotechnology, Clinical-stage, Neurological Disorders, AMPAR, TARP8, Clinical Trials, SEC Filing, 10-Q, Biopharma, Drug Development, Diabetic Peripheral Neuropathic Pain, Bipolar Mania, Public Offering, NeuroPace, Janssen License, Financial Results, Risk Factors